- Physiomics said it had extended a collaboration pact with Merck for the next calendar year related to cancer treatments.

Physiomics and Merck had entered into contracts with a total value of £435k, for projects envisaged to be completed during calendar 2019.

They spanned a range of drug targets and treatment types in both pre-clinical and clinical settings.

The two companies provisionally agreed that they would aim to publish selected elements of their work at one or more major conferences in 2019.

'We are now entering the eighth year of our relationship with Merck, during which time we have provided a range of pre-clinical and clinical predictive modelling services using our virtual tumour technology,' chief executive Jim Millen said.

'We remain immensely proud to be working with one of the world's foremost pharmaceutical companies, in an area as important and rapidly growing as oncology.'

'We look forward to this collaboration continuing.'

At 8:14am: [LON:PYC] Physiomics PLC share price was +0.15p at 4.3p

Story provided by